ARTICLE | Clinical News
Rytary regulatory update
December 7, 2015 8:00 AM UTC
The European Commission approved Numient carbidopa/levodopa from Impax for symptomatic treatment of adults with Parkinson’s disease. Impax markets the product as Rytary in the U.S. (see BioCentury, J...